Introduction {#sec1-0300060518816834}
============

Diabetic retinopathy (DR) is a major vascular complication that frequently leads to blindness.^[@bibr1-0300060518816834]^ Worldwide incidences of DR and vision-threatening DR have been estimated to reach 191.0 million and 56.3 million people, respectively, by 2030, due to the increasing prevalence of diabetes.^[@bibr2-0300060518816834]^ The prevalences of DR in the Chinese general population and in Chinese diabetic patients were recently estimated at 1.3% and 23%, respectively.^[@bibr3-0300060518816834]^ Previous studies have suggested that genetic factors and environmental factors contribute to the development of DR.^[@bibr4-0300060518816834]^ The methylenetetrahydrofolate reductase (*MTHFR*) gene, which catalyzes the methylation of homocysteine to methionine,^[@bibr5-0300060518816834]^ is widely regarded as a candidate gene for risk of diabetes mellitus. A single nucleotide polymorphism in the *MTHFR* gene at nucleotide C677T can destroy its enzyme activity and cause hyperhomocysteinemia.^[@bibr6-0300060518816834]^ Because of this critical functional influence, it is readily postulated that *MTHFR* C677T polymorphisms contribute to the development of DR, and a number of studies have addressed their role in DR.^[@bibr7-0300060518816834][@bibr8-0300060518816834]--[@bibr9-0300060518816834]^ Data supporting a potential relationship between *MTHFR* C677T polymorphisms and risk of DR within the Chinese population remain controversial, likely because of the lower statistical power of individual studies, which use smaller sample sizes than meta-analyses. In addition, the lack of repeatable results may be due to inconsistent genotyping or lifestyle assessments. Therefore, we performed the present meta-analysis to determine the association between the *MTHFR* C677T polymorphisms and risk of DR within the Chinese population, in order to reduce the influence of distinctive genetic backgrounds or lifestyles.

Materials and methods {#sec2-0300060518816834}
=====================

Identification and selection of studies {#sec3-0300060518816834}
---------------------------------------

Studies that assessed the relationship between the *MTHFR* C677T polymorphisms and the risk of DR, published before April 2017, were considered in this study. Five databases (PubMed, EMBASE, Web of Science, Cochrane Library, and Chinese National Knowledge Infrastructure) were used for literature searches of open access studies. A combination of keywords ("MTHFR" OR "methylenetetrahydrofolate reductase" AND "DR") was used. Additionally, we carefully reviewed the retrieved references to ensure inclusion of the most comprehensive studies.

Inclusion criteria were as follows: (1) studies using a case-control design that assessed the relationship between the *MTHFR* C677T polymorphisms and risk of DR; (2) studies with sufficient genotype data for DR cases and healthy controls; (3) studies in which all cases and controls were Chinese individuals; and (4) studies in which DR was assessed by fundus photography or fundus fluorescein angiography, performed in accordance with the methods designated by the 3rd National Congress of Ophthalmology in China. Exclusion criteria were as follows: (1) studies that comprised overlapping cohorts; (2) studies in which data could not be extracted; (3) studies that did not use the case-control design; and (4) studies that were abstracts or reviews.

Data extraction {#sec4-0300060518816834}
---------------

Two investigators screened the potentially relevant studies and extracted the following data: first author's name, publication year, geographic area, types of controls, sample size, and availability of genotype information regarding the *MTHFR* C677T polymorphisms. The types of controls were stratified as healthy controls and nondiabetic retinopathy (NDR) controls. The titles and abstracts were reviewed for each retrieved document, and the full articles were reviewed if the titles and abstracts did not clearly indicate whether the study was appropriate for this meta-analysis. Discrepancies between the two investigators were resolved by discussion.

Statistical analysis {#sec5-0300060518816834}
--------------------

Odds ratios (ORs) and 95% confidence intervals (CIs) were generated for the *MTHFR* C677T polymorphisms and risk of DR. Models of T versus C, TT versus CC, TT versus (TC+CC) and (TT+TC) versus CC were examined with respect to the risk of DR. The heterogeneity of pooled results, as well as the Hardy-Weinberg equilibrium (HWE) in controls, were assessed by the I^2^ statistic, based on the Q-test.^[@bibr10-0300060518816834]^ A random-effects model was applied to estimate the pooled ORs when P~heterogeneity~ \< 0.1 or I^2^ \> 50%; otherwise, a fixed-effects model was adopted. The overall statistical significances of ORs were evaluated by Z-test. Both fixed-effects and random-effects models for each pooled OR were computed for sensitivity analysis. All statistical analysis was performed with Stata version 12 (StataCorp LP, College Station, TX, USA); p-values less than 0.05 were considered significant. Additionally, we performed subgroup analysis by geographic area, to assess the relationship between *MTHFR* C677T and risk of DR in specific regions of China.

Results {#sec6-0300060518816834}
=======

Research characteristics {#sec7-0300060518816834}
------------------------

Forty-two publications were identified that assessed relationships between *MTHFR* polymorphisms and risk of DR. In total, eight studies^[@bibr11-0300060518816834][@bibr12-0300060518816834][@bibr13-0300060518816834][@bibr14-0300060518816834][@bibr15-0300060518816834][@bibr16-0300060518816834][@bibr17-0300060518816834]--[@bibr18-0300060518816834]^, which met our inclusion criteria, were used in this report. The publication years of the included studies ranged from 2001 to 2012. [Figure 1](#fig1-0300060518816834){ref-type="fig"} shows the detailed screening process used in our analysis. Finally, 600 DR cases, 363 healthy controls, and 646 NDR controls were included in the current study. The main characteristics of the eight articles are listed in [Table 1](#table1-0300060518816834){ref-type="table"}.

![Flow diagram of the literature search.](10.1177_0300060518816834-fig1){#fig1-0300060518816834}

###### 

Characteristics of studies included in the meta-analysis.

![](10.1177_0300060518816834-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference    Geographic area   Number of DR cases   Number of healthy controls   Number of NDR controls   Demographic data                                                                              Cases   Healthy controls   NDR controls   HWE                                    
  ------------ ----------------- -------------------- ---------------------------- ------------------------ --------------------------------------------------------------------------------------------- ------- ------------------ -------------- ----- ---- ---- ---- ---- ---- ------- -------
  Wang 2001    Guangdong         62                   85                           117                      Sex (M/F): DR 36/26; NDR 63/54; HC 39/46Age (M/S): DR 62.5/8.1; NDR 59.4/14.9; HC 41.8/17.1   8       27                 27             37    38   10   57   48   12   0.959   0.689

  Yang 2001    Beijing           60                   62                           102                      Sex (M/F): DR 31/29; NDR 56/46; HC 34/28Age (M/S): DR 50.7/12.1; NDR 63/8.8; HC 52.6/14.9     8       33                 19             26    28   8    32   56   14   0.914   0.178

  Guo 2002     Beijing           52                   28                           52                       Sex (M/F): DR 21/31; NDR 25/27; HC 12/16Age (M/S): DR 54.6/12;\                               5       23                 24             12    11   5    17   23   12   0.392   0.440
                                                                                                            NDR 55.2/6.9; HC 56.6/10.8                                                                                                                                                     

  Sun 2003     Hubei             110                  57                           98                       Sex (M/F): DR 64/46; NDR 56/42; HC 34/23Age (M/S): DR 55.6/6.7; NDR 54.7/7.1; HC 42.3/6.1     33      46                 31             31    16   10   51   29   18   0.008   0.001

  Huang 2005   Jiangsu           50                   47                                                    ---                                                                                           17      25                 8              26    18   3                   0.961   

  Liu 2006     Tianjin           44                   84                                                    Sex (M/F): DR 27/17; HC 48/36Age (M/S): DR 51.9/7.5; HC 54/13.2                               18      16                 10             47    25   12                  0.010   

  Ren 2011     Tianjin           161                                               213                      ---                                                                                           26      78                 57                             77   95   41           0.233

  Wei 2012     Guangdong         61                                                64                       Sex (M/F): DR 24/37; NDR 27/37Age (M/S): DR 59.3/-; NDR 58.3/-                                33      25                 3                              37   21   6            0.254
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DR: diabetic retinopathy; HC: healthy controls; NDR: nondiabetic retinopathy; Sex (M/F): Sex (male/female); Age (M/S): Age (mean/standard deviation); *P~1~*: for healthy controls; *P~2~*: for NDR controls

Meta-analysis results {#sec8-0300060518816834}
---------------------

We compared DR cases with the NDR group. Analysis of primary pooled statistics showed that all polymorphisms of *MTHFR* C677T (T vs. C, OR: 2.14, 95% CI: 1.55--2.97; TT vs. CC, OR: 4.19, 95% CI: 2.09--8.41; TT + CT vs. CC, OR: 2.83, 95% CI: 1.86--4.40; TT vs. CC + CT, OR: 2.48, 95% CI: 1.52--4.05) ([Table 2](#table2-0300060518816834){ref-type="table"}, [Figure 2](#fig2-0300060518816834){ref-type="fig"}) had a significantly increased risk of DR. Moreover, subgroup analysis by geographic area showed significantly positive associations among northern Chinese in three analysis models, as well as a significantly positive association among southern Chinese in the (TT+CT vs. CC) model.

![Forest plots of all selected studies regarding the association between *MTHFR* C677T polymorphism and diabetic retinopathy risk within the Chinese population under the allele model (comparison between diabetic retinopathy and nondiabetic retinopathy controls).](10.1177_0300060518816834-fig2){#fig2-0300060518816834}

###### 

Association of the *MTHFR* C677T polymorphism with diabetic retinopathy susceptibility (diabetic retinopathy vs. nondiabetic retinopathy controls).

![](10.1177_0300060518816834-table2)

  Analysis model   n                OR~r~ (95% CI)   OR~f~ (95% CI)          P~h~                    
  ---------------- ---------------- ---------------- ----------------------- ----------------------- -------
  T vs. C          Total analysis   6                **2.14 (1.55--2.97)**   **2.16 (1.82--2.56)**   0.006
                   South China      3                2.03 (0.95--4.38)       2.16 (1.66--2.81**)**   0.000
                   North China      3                **2.15 (1.72--2.70)**   **2.15 (1.72--2.70)**   0.768
  TT vs. CC        Total analysis   6                **4.19 (2.09--8.41)**   **4.14 (2.93--5.86)**   0.006
                   South China      3                3.08 (0.59--15.98)      3.56 (2.14--5.90)       0.000
                   North China      3                **4.72 (2.93--7.60)**   **4.73 (2.94--7.61)**   0.735
  TT vs. CC+CT     Total analysis   6                **2.48 (1.52--4.05)**   **2.49 (1.87--3.30)**   0.028
                   South China      3                2.01 (0.56--7.24)       2.44 (1.55--3.84)       0.002
                   North China      3                **2.52 (1.75--3.62)**   **2.52 (2.15--3.72)**   0.834
  TT+CT vs. CC     Total analysis   6                **2.86 (1.86--4.40)**   **2.83 (1.86--4.40)**   0.056
                   South China      3                **2.60 (1.08--6.25)**   **2.57 (1.76--3.75)**   0.008
                   North China      3                **3.13 (2.09--4.69)**   **3.13 (2.10--4.69)**   0.765

ORr: Odds ratio for random-effects model; ORf: Odds ratio for fixed-effects model; P~h~ *P* value for heterogeneity test; North China includes Beijing and Tianjin; South China includes Hubei, Guangdong, and Jiangsu. Bold values indicate significant results.

We compared DR cases with the healthy group. Analysis of primary pooled statistics showed that all polymorphisms of *MTHFR* C677T (T vs. C, OR: 2.48, 95% CI: 1.99--3.09; TT vs. CC, OR: 4.92, 95% CI: 3.18--7.62; TT + CT vs. CC, OR: 3.22, 95% CI: 2.32--4.48; TT vs. CC + CT, OR: 3.11, 95% CI: 1.83--5.28) could increase the risk of DR; subgroup analysis showed that this risk was also increased specifically in northern Chinese and southern Chinese ([Table 3](#table3-0300060518816834){ref-type="table"}, [Figure 3](#fig3-0300060518816834){ref-type="fig"}).

![Forest plots of all selected studies regarding the association between *MTHFR* C677T polymorphism and diabetic retinopathy risk within the Chinese population under the allele model (comparison between diabetic retinopathy and healthy controls).](10.1177_0300060518816834-fig3){#fig3-0300060518816834}

###### 

Association of the *MTHFR* C677T polymorphism with diabetic retinopathy susceptibility (diabetic retinopathy vs. healthy controls).

![](10.1177_0300060518816834-table3)

  Analysis model   n                ORr (95% CI)   ORf (95% CI)             P~h~                    
  ---------------- ---------------- -------------- ------------------------ ----------------------- -------
  T vs. C          Total analysis   6              **2.48 (1.93--3.19)**    **2.48 (1.99--3.09)**   0.263
                   South China      3              **2.53 (1.72--3.71)**    **2.54 (1.89--3.42)**   0.196
                   North China      3              **2.43 (1.61--3.68)**    **2.40 (1.74--3.32)**   0.209
  TT vs. CC        Total analysis   6              **5.21 (2.81--9.64)**    **4.92 (3.18--7.62)**   0.109
                   South China      3              **5.25 (2.03--13.57)**   **4.97 (2.74--9.05)**   0.107
                   North China      3              **5.33 (1.92--14.80)**   **4.85 (2.56--9.20)**   0.104
  TT vs. CC+CT     Total analysis   6              **2.92 (1.96--4.36)**    **3.11 (1.83--5.28)**   0.379
                   South China      3              **3.14 (1.45--6.77)**    **2.75 (1.58--4.78)**   0.148
                   North China      3              **2.69 (1.53--4.74)**    **2.93 (2.00--4.30)**   0.510
  TT+CT vs. CC     Total analysis   6              **3.25 (2.21--4.77)**    **3.22 (2.32--4.48)**   0.265
                   South China      3              **3.15 (2.02--4.90)**    **3.21 (2.08--4.97)**   0.391
                   North China      3              **3.59 (1.60--8.06)**    **3.23 (1.95--5.36)**   0.102

ORr: Odds ratio for random-effects model; ORf: Odds ratio for fixed-effects model; P~h~ *P* value for heterogeneity test; North China includes Beijing and Tianjin; South China includes Hubei, Guangdong, and Jiangsu. Bold values indicate significant results.

Sensitivity analysis {#sec9-0300060518816834}
--------------------

To determine whether the results were stable and robust, sensitivity analyses of both fixed-effects and random-effects models were performed. The results showed that these two models were consistent and stable in each analysis ([Table 2](#table2-0300060518816834){ref-type="table"}, [Table 3](#table3-0300060518816834){ref-type="table"}).

Discussion {#sec10-0300060518816834}
==========

Many articles have been published regarding analysis of the relationship between *MTHFR* C677T polymorphisms and risk of DR; however, no comprehensive conclusions have been made. Thus far, three meta-analyses have been published regarding *MTHFR* C677T polymorphisms and risk of DR.^[@bibr19-0300060518816834][@bibr20-0300060518816834]--[@bibr21-0300060518816834]^ Nevertheless, the results were inconclusive and inconsistent. Limitations in these three meta-analyses indicated that further studies with larger populations and more rigorous designs are needed.^[@bibr19-0300060518816834][@bibr20-0300060518816834]--[@bibr21-0300060518816834]^ Individual studies might yield disparate results, due to the regional and individual differences among populations, as well as the limited number of cases in each study. Unique lifestyles among diverse ethnic groups may interact differently with particular genetic traits.^[@bibr22-0300060518816834]^ To reduce the influence of these factors in the overall analysis, we performed this report to further explore the relationship between *MTHFR* C677T polymorphisms and risk of DR within the Chinese population.

The current meta-analysis involved eight studies with 600 DR cases, 363 healthy controls, and 646 NDR controls. The results of this analysis showed a positive relationship between *MTHFR* C677T polymorphisms and risk of DR in overall analyses of DR patients compared with healthy controls or NDR controls. To control for the effects of geographic background on these results, we also performed subgroup analysis with respect to geographic areas; these also showed positive relationships between *MTHFR* C677T polymorphisms and risk of DR in patients in different regions, compared with healthy controls or NDR controls.

There were several limitations in this study. First, we only searched and included openly available articles; therefore, some other unpublished articles or gray literature could have been missed, although they might meet our inclusion criteria. Second, the sample size for our meta-analysis was low, and we could not perform some other subgroup analyses, such as those involving age, exposure time, or smoking habits, owing to the limited data in the original papers. Third, DR is a complex disease involving a variety of factors, both environmental and genetic.^[@bibr23-0300060518816834]^ However, many of the included studies did not consider some environmental factors, which may influence the risk of DR. Moreover, we did not explore the publication bias in this study, owing to limitations of the funnel plot analysis, which requires a greater number of studies than we had available.

Conclusion {#sec11-0300060518816834}
==========

Our study found a positive relationship between *MTHFR* C677T polymorphisms and risk of DR within the Chinese population. However, owing to some limitations in this meta-analysis, further studies with different environmental backgrounds are required to further explore gene-gene and gene-environment influences on *MTHFR* C677T polymorphisms and risk of DR.
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